Eli Lilly slashes guidance in face of pricing pressures and growing generic competition

Facing increasing pricing pressures and growing generic competition, Eli Lilly & Co. on Tuesday cut its full-year guidance, sparking a selloff that sent shares of the drugmaker down 2.5%.